Disease · MONDO_0006325

ocular melanoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. ocular melanoma. Diseases, record MONDO_0006325. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006325

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: ocular melanoma; Open Targets
Open Targets ID: MONDO_0006325; Open Targets
Other names: eye melanoma, eye melanoma (disease), eyeball of camera-type eye melanoma, eyeball of camera-type eye melanoma (disease), melanoma (disease) of eyeball of camera-type eye, melanoma of eye, melanoma of the eye; Open Targets
Disease Ontology: DOID:1752; Disease Ontology
NCI Thesaurus: C8562; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 1 of its 20 drugs, from ClinicalTrials.gov; Open Targets

Drugs20

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
MELPHALAN	CHEMBL852	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ALDESLEUKIN	CHEMBL1201438	Protein	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
LENALIDOMIDE	CHEMBL848	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
SUNITINIB MALATE	CHEMBL1567	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
TEMOZOLOMIDE	CHEMBL810	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CABOZANTINIB	CHEMBL2105717	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DACARBAZINE	CHEMBL476	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
FLUDARABINE	CHEMBL1568	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 20

See all 20 drugs

Targets41

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	2	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	2	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
ABL1	Bcr/Abl fusion protein	1	Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor	Phase 2	https://conductscience.org/library/genes/25	Drugs and targets
ALDH5A1	Succinate-semialdehyde dehydrogenase, mitochondrial	1	Succinate semialdehyde dehydrogenase inhibitor	Phase 1/2	https://conductscience.org/library/genes/7915	Drugs and targets
BCR	Bcr/Abl fusion protein	1	Bcr/Abl fusion protein inhibitor	Phase 2	https://conductscience.org/library/genes/613	Drugs and targets
CRBN	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 2	https://conductscience.org/library/genes/51185	Drugs and targets
CSF1R	Macrophage colony-stimulating factor 1 receptor	1	Macrophage colony stimulating factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/1436	Drugs and targets
CTLA4	Cytotoxic T-lymphocyte protein 4	1	Cytotoxic T-lymphocyte protein 4 inhibitor	Phase 2	https://conductscience.org/library/genes/1493	Drugs and targets
CUL4A	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 2	https://conductscience.org/library/genes/8451	Drugs and targets

1 to 10 of 41

See all 41 targets

Trials13

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01835145	Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery	Phase 2	47	2019-04-26	Recurrent Uveal Melanoma, Stage III Uveal Melanoma AJCC v7, Stage IIIA Uveal Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7, Stage IIIC Uveal Melanoma AJCC v7, Stage IV Uveal Melanoma AJCC v7	CABOZANTINIB, DACARBAZINE, TEMOZOLOMIDE	Its record names the disease	ClinicalTrials.gov
NCT00925132	Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat	Phase 1/2	39	2017-07-02	Metastatic Melanoma	DECITABINE, PANOBINOSTAT, TEMOZOLOMIDE	Its record names the disease	ClinicalTrials.gov
NCT01814046	Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma	Phase 2	24	2017-07-24	Metastatic Ocular Melanoma, Metastatic Uveal Melanoma	ALDESLEUKIN, CYCLOPHOSPHAMIDE, FLUDARABINE	Its record names the disease	ClinicalTrials.gov
NCT00109005	Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma	Phase 2	17	2012-10-30	Melanoma	LENALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT00482911	Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma	Phase 2	12	2012-11-14	Intraocular Melanoma, Malignant Conjunctival Neoplasm	CYCLOPHOSPHAMIDE, LENALIDOMIDE, SUNITINIB MALATE	Its record names the disease	ClinicalTrials.gov
NCT03850691	Radiation and Combination Immunotherapy for Melanoma	Phase 2	4	2023-03-03	Metastatic Melanoma	ALDESLEUKIN, IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT03919292	Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca	Phase 1/2	80		Solid Tumor, Adult	DIVALPROEX SODIUM, NERATINIB	Its record names the disease	ClinicalTrials.gov
NCT00489944	Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma	Phase 2	50		Intraocular Melanoma	CISPLATIN, SUNITINIB MALATE, TAMOXIFEN CITRATE	Its record names the disease	ClinicalTrials.gov
NCT05022901	An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma	Phase 3	30		Metastatic Ocular Melanoma, Metastatic Uveal Melanoma	MELPHALAN	Its record names the disease	ClinicalTrials.gov
NCT00085306	Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma	Phase 2	21		Stage IV Melanoma, Recurrent Melanoma	INTERFERON BETA	Its record names the disease	ClinicalTrials.gov

1 to 10 of 13

See all 13 trials

Comparisons in its trials11

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Arm I (Cabozantinib-s-malate) vs Arm II (Temozolomide or Dacarbazine): Confirmed Response Rate as Determined by the RECIST Criteria (Version 1.1)	0 of 31	0 of 15	46	NCT01835145	Trial comparisons
Cells + High Dose Aldesleukin vs Cells and no High Dose Aldesleukin: Count of Participants With Changes in Visual Symptoms	1 of 22	0 of 2	24	NCT01814046	Trial comparisons
Cells + High Dose Aldesleukin vs Cells and no High Dose Aldesleukin: Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0)	22 of 22	2 of 2	24	NCT01814046	Trial comparisons
Cohort 1 - 25 mg Lenalidomide (Revlimid) vs Cohort 2 - 5 mg Lenalidomide (Revlimid): Number of Participants With Adverse Events	8 of 8	9 of 9	17	NCT00109005	Trial comparisons
Cohort 1 - 25 mg Lenalidomide (Revlimid) vs Cohort 2 - 5 mg Lenalidomide (Revlimid): serious adverse events	1 of 8	1 of 9	17	NCT00109005	Trial comparisons
Cohort 1-lenalidomide & Cyclophosphamide vs Cohort 2-sunitinib & Cyclophosphamide: Toxicity	3 of 3	8 of 9	12	NCT00482911	Trial comparisons
Cohort 1-lenalidomide & Cyclophosphamide vs Cohort 2-sunitinib & Cyclophosphamide: serious adverse events	0 of 3	2 of 9	12	NCT00482911	Trial comparisons
Cohort 1: Nivolumab vs Cohort 2: Nivolumab & Ipilimumab: Objective Response Rate (ORR)	1 of 1	1 of 3	4	NCT03850691	Trial comparisons
Cohort 1: Nivolumab vs Cohort 2: Nivolumab & Ipilimumab: Safety and Tolerability of Sequential Combination Immunotherapy (Incidence of Stopping Rule Events)	0 of 1	0 of 3	4	NCT03850691	Trial comparisons
Cohort 1: Nivolumab vs Cohort 2: Nivolumab & Ipilimumab: deaths from any cause	1 of 1	2 of 3	4	NCT03850691	Trial comparisons

1 to 10 of 11

See all 11 comparisons in its trials

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
34482636	DERIVED	1	PubMed
33170593	DERIVED	1	PubMed
28395880	DERIVED	1	PubMed
25062770	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006325

GET https://conductscience.org/api/diseases/v1/MONDO_0006325/targets?page=2

API reference For AI assistants